Literature DB >> 10933673

Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.

F M Müller, M Weig, J Peter, T J Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10933673     DOI： 10.1093/jac/46.2.338

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  15 in total

1.  In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

Authors:  M A Pfaller; R Hollis; B P Goldstein; S Messer; D Diekema; T Henkel
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

2.  Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.

Authors:  Kathrin Heyn; Antje Tredup; Stefanie Salvenmoser; Frank-Michael C Müller
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression.

Authors:  Emmanuelle Pinjon; Colin J Jackson; Steven L Kelly; Dominique Sanglard; Gary Moran; David C Coleman; Derek J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

Authors:  Stefano P Bachmann; Thomas F Patterson; José L López-Ribot
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avenissian; Yue Fu; Scott G Filler; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  M Weig; F M Müller
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.

Authors:  Lingmei Sun; Shujuan Sun; Aixia Cheng; Xiuzhen Wu; Yu Zhang; Hongxiang Lou
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

9.  Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Authors:  Paul A Mann; Raulo M Parmegiani; Shui-Qing Wei; Cara A Mendrick; Xin Li; David Loebenberg; Beth DiDomenico; Roberta S Hare; Scott S Walker; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 10.  Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.

Authors:  Joanna Filioti; Kleomenis Spiroglou; Emmanuel Roilides
Journal:  Intensive Care Med       Date:  2007-05-15       Impact factor: 17.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.